More than 22,000 pharmaceutical jobs were cut in 2025 as companies brace for a $300 billion patent cliff. But the real story is not workforce reduction. It’s the reshaping of competition, value and decision-making across the entire market.

Pharmaceutical companies must move beyond cost-cutting and incremental innovation by embedding evidence, market access and economic value into decision-making from the earliest stages of development to remain viable in a structurally different market.

Read More

Thank you for your interest in our content. Registering allows you to access a wide range of informative articles, briefs, and whitepapers throughout the site.

Privacy is important. We do not share registrant information with anyone outside of Numerof & Associates. For details, please see our Privacy Policy. Subscribers to our mailings can unsubscribe instantly at any time.

×